Phase II study of topotecan and amrubicin for metastatic or relapsed small-cell lung cancer - Topotecan and amrubicin for metastatic or relapsed small-cell lung cancer

Okayama Lung Cancer Study Group0 sites30 target enrollmentSeptember 12, 2005

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Not specified
Sponsor: Okayama Lung Cancer Study Group
Enrollment: 30
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This phase II study showed the favorable efficacy and moderate safety profiles of a topotecan and amrubicin two-drug combination especially in relapsed patients with ED-SCLC.

Registry

who.int

Start Date

September 12, 2005

End Date

April 1, 2009

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Okayama Lung Cancer Study Group

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Active concomitant malignancy Active interstitial pneumonia Massive effusions Unstable angina, recent myocardial infarction Uncontrolled diabetes Severe active infection Other severe complications Pregnant or lactating women Inappropriate condition for this study judged by physicians.